Powered 500 · 2026POWEREDS. 013 of 500
Schleifer founded Regeneron in 1988 and has spent 35-plus years building it into a $13 billion biotech giant whose drugs — Dupixent, Eylea, and REGEN-COV — now treat millions across allergies, blindness, cancer, and COVID-19.
Leonard Schleifer is Founder, President, and CEO of Regeneron Pharmaceuticals, the biotechnology company generating over $13 billion in annual revenue.
Schleifer co-founded Regeneron in 1988 with George Yancopoulos and has led it for over 35 years. The company's portfolio includes Eylea, Dupixent, Libtayo, and the REGEN-COV antibody cocktail used to treat COVID-19. Schleifer holds both an MD and a PhD.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
